Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Syndax Pharmaceuticals Inc’s stock clocked out at $16.12, down -1.29% from its previous closing price of $16.33. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 1.8 million shares were traded. SNDX stock price reached its highest trading level at $16.885 during the session, while it also had its lowest trading level at $15.94.
Ratios:
To gain a deeper understanding of SNDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 2.19 whereas as Long-Term Debt/Eq ratio is at 2.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on August 05, 2025, Reiterated its Buy rating but revised its target price to $56 from $43 previously.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $18. On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $37.UBS initiated its Buy rating on October 24, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Podlesak Dennis sold 19,200 shares for $15.84 per share. The transaction valued at 304,170 led to the insider holds 191,763 shares of the business.
Podlesak Dennis sold 19,200 shares of SNDX for $298,408 on Aug 15 ’25. The Director now owns 191,763 shares after completing the transaction at $15.54 per share. On Aug 14 ’25, another insider, Podlesak Dennis, who serves as the Director of the company, sold 19,200 shares for $14.19 each. As a result, the insider received 272,521 and left with 191,763 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1388607616 and an Enterprise Value of 1265423872. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.76 while its Price-to-Book (P/B) ratio in mrq is 8.81. Its current Enterprise Value per Revenue stands at 16.237 whereas that against EBITDA is -3.732.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.72, which has changed by -0.17964375 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $22.50, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is 38.69%, while the 200-Day Moving Average is calculated to be 25.60%.
Shares Statistics:
It appears that SNDX traded 2.20M shares on average per day over the past three months and 2155870 shares per day over the past ten days. A total of 86.06M shares are outstanding, with a floating share count of 83.35M. Insiders hold about 3.24% of the company’s shares, while institutions hold 119.72% stake in the company. Shares short for SNDX as of 1755216000 were 20605895 with a Short Ratio of 9.38, compared to 1752537600 on 23691424. Therefore, it implies a Short% of Shares Outstanding of 20605895 and a Short% of Float of 27.01.
Earnings Estimates
The current rating of Syndax Pharmaceuticals Inc (SNDX) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.29 and low estimates of -$0.93.
Analysts are recommending an EPS of between -$2.64 and -$3.7 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$1.87, with 10.0 analysts recommending between -$0.51 and -$3.01.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $48.57M. It ranges from a high estimate of $60.17M to a low estimate of $43.5M. As of the current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $12.5MFor the next quarter, 10 analysts are estimating revenue of $62.57M. There is a high estimate of $78.97M for the next quarter, whereas the lowest estimate is $50.9M.
A total of 10 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $194.19M, while the lowest revenue estimate was $153M, resulting in an average revenue estimate of $169.24M. In the same quarter a year ago, actual revenue was $23.68MBased on 10 analysts’ estimates, the company’s revenue will be $348.84M in the next fiscal year. The high estimate is $448.87M and the low estimate is $257.7M.
